1. Home
  2. ATNM vs TACT Comparison

ATNM vs TACT Comparison

Compare ATNM & TACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.38

Market Cap

50.2M

Sector

Health Care

ML Signal

HOLD

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$4.47

Market Cap

46.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATNM
TACT
Founded
2000
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
50.2M
46.1M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
ATNM
TACT
Price
$1.38
$4.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$5.00
AVG Volume (30 Days)
223.5K
49.1K
Earning Date
11-14-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$90,000.00
$50,258,000.00
Revenue This Year
N/A
$21.67
Revenue Next Year
N/A
$7.63
P/E Ratio
N/A
N/A
Revenue Growth
11.11
8.27
52 Week Low
$1.03
$3.12
52 Week High
$2.41
$5.70

Technical Indicators

Market Signals
Indicator
ATNM
TACT
Relative Strength Index (RSI) 47.64 51.95
Support Level $1.25 $4.30
Resistance Level $1.48 $4.75
Average True Range (ATR) 0.10 0.25
MACD 0.01 0.05
Stochastic Oscillator 35.85 64.71

Price Performance

Historical Comparison
ATNM
TACT

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

Share on Social Networks: